Advances in Anti-VEGF Therapies for Retinal Diseases
Emerging anti-VEGF agents are showing promise in treating retinal diseases with enhanced durability and anatomic outcomes.
A recent discussion highlighted the structural differences among newer second-generation anti-VEGF agents and their implications for clinical efficacy and treatment durability.
Real-World Experiences and Evidence
The discussion also touched on real-world experiences and evidence regarding extended treatment intervals and sustained disease control with these newer therapies.
Stewart, MD, summarized the key takeaways from the discussion, sharing a case of an 83-year-old woman with diabetic macular edema (DME).
She had undergone temporal grid laser photocoagulation for macular edema and received bevacizumab (Avastin; Genentech, Inc) intravitreal injections every 4 to 6 weeks.
Author's summary: New anti-VEGF agents enhance retinal disease treatment.